A second domestic HPV vaccine has been approved, giving cities more options to promote free vaccination

2022-05-12 0 By

The Paper reporter Hu Danping on March 24, the State Food and Drug Administration (SFDA) posted information on the official website of the double valent human papillomavirus (HPV) vaccine approval document of Zerun Biotechnology Co., LTD., a subsidiary of Watson Biological Holding Company, which means the second domestic HPV vaccine has been approved to market.The approval of another domestic HPV vaccine will add another option for places announcing free HPV vaccinations.China will have five HPV vaccines to choose from as newly approved HPV vaccines become available on the market.Among them, two domestic products are Vantime bivalent HPV vaccine and the newly approved Watson bivalent HPV vaccine. There are also three imported HPV vaccines, namely GlaxoSmithKline bivalent HPV vaccine, Merck quadrivalent HPV vaccine and nine-valent HPV vaccine.HPV vaccination is one of the most cost-effective means to eliminate cervical cancer.Currently HPV vaccine has not been included in the national immunization program or medical insurance coverage in China, according to the principle of self-pay and voluntary vaccination.In August 2020, China’s first free HPV vaccine was launched in Zhungar Banner, Ordos city. The zhungar Banner government provided free HPV vaccine to about 8,500 middle school girls between the ages of 13 and 18.One month later, Xiamen Municipal Health Commission also issued the notice of implementation Plan of Domestic 2-valent HPV vaccine in Xiamen, and decided to provide domestic 2-valent HPV vaccine and implement voluntary free vaccination for school-age girls in Xiamen during 2020-2022.In October 2021, the construction of healthy city promoting health action mode innovation pilot projects in China, including shandong jinan, xiamen, fujian, sichuan, chengdu, henan, zhengzhou city, guangdong shenzhen, 15 cities in the health action innovation mode the first batch of pilot cities in China, one of the important work of HPV vaccine coverage.Since then, several cities on the list of 15 pilot cities, including Jinan in Shandong Province, Chengdu in Sichuan Province, Wuxi in Jiangsu Province and Lianyun District in Lianyungang City, have implemented or announced that they will soon offer free HPV vaccination to school-age girls.Even in some of the more economically developed regions, free HPV vaccination has gone from pilot cities to provenance-wide implementation.In November 2021, the Work Plan of Free HPV Vaccination for School-age Girls in Guangdong Province (2022-2024) was released. Starting from September 2022, girls under the age of 14 who have school status in Guangdong province and have entered the first grade of junior middle school since September and have not been vaccinated against HPV will be informed, voluntary and free of charge.Implementation of HPV vaccination.The vaccine used in the project was domestic bivalent HPV vaccine. Each city entrusted the provincial CDC to sign the purchase contract with the supplier after the purchase negotiation, and distributed the vaccine to the vaccination sites in each district step by step.Since 2022, more areas have been added to the list of areas that have promoted free HPV vaccination for school-age girls,A number of places, including Zhengzhou in Henan province, Shijiazhuang and Tangshan in Hebei Province, Hainan Province, Chongqing in Fujian Province, Mianyang in Sichuan Province and Linyi county in Dezhou City in Shandong Province, have recently launched or announced that they will soon offer free HPV vaccination to school-age girls.Qiao Youlin, a professor at the School of Herd Medicine and Public Health of Peking Union Medical College, told Thepaper.cn that promoting free HPV vaccination is limited by two factors: financial support and vaccine production.As more domestic cervical cancer vaccines are approved for the market, volume will no longer be a constraint.China’s first home-made HPV vaccine is priced at 329 yuan per dose, almost half the price of the imported quadruvalent HPV vaccine.Therefore, the domestic bivalent HPV vaccine has become the first choice for free vaccination in many places.According to thepaper.cn, guangdong and Hainan provinces, Xiamen city in Fujian Province, Tangshan city in Hebei Province, and Linyi County in Dezhou City in Shandong Province have all confirmed the use of domestic bivalent HPV vaccine for free vaccination.In addition to the clear requirement to carry out the model of free domestic bivalent HPV vaccine vaccination, there are also more exploration, for example, Chengdu, Sichuan province is to carry out the universal HPV vaccine subsidy program for 13-14 year old school girls, girls of the right age can choose between domestic/imported bivalent and imported quadruvalent HPV vaccine.The parents (guardians) shall bear the difference of the vaccine cost and the vaccination service fee (20 yuan/dose) after the subsidy.”We hope to bring down the price of HPV vaccine through centralized government procurement in the future.”Song Wei, director of the Women’s and Children’s Department of the Chengdu Health Commission, who is involved in the development of the SUBSIDY program for HPV vaccination for girls of school age in Chengdu, told the Paper that HPV vaccine has always been a seller’s market, but if the production increases and there are more vaccines to choose from, it will be a buyer’s market, and the price should come down.The approval of Watson Bivalent HPV vaccine will give more cities a new option to promote free vaccination.Thepaper learned from Watson Biological that the bivalent HPV vaccine approved this time will be produced in Yunnan, and a modern production base with a capacity of 30 million doses of bivalent HPV vaccine will be designed according to The requirements of Chinese GMP and WHO regulations.According to Watson Bio, the bivalent HPV vaccine is suitable for women aged 9 to 30 years, and can also be used for women aged 9 to 14 years, two doses of the vaccine can be used for different age groups, reducing the cost of vaccination.